查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1595485

庞贝氏症市场：依治疗类型、分子类型、剂型、给药途径分类 - 全球预测 2025-2030

Pompe Disease Market by Therapy Type (Enzyme, Substrate), Molecule Type (Biologics, Small Molecules), Dosage Form, Route of Administration - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年庞贝氏症市场价值为15亿美元，预计2024年将达15.9亿美元，复合年增长率为5.61%，预计2030年将达到22.1亿美元。

庞贝氏症是一种由体内细胞内肝醣累积引起的罕见遗传疾病，它呈现出独特的市场环境，其特征是专门的治疗需求和挑战。该市场以酵素替代疗法和潜在的基因疗法为中心，可治疗从婴儿期到迟发性疾病的多种疾病类型。这种疾病的使人衰弱的性质强调了治疗的必要性，它影响心臟和骨骼肌，凸显了持续医疗干预的关键作用。主要应用领域包括遗传研究、酵素开发和病患管理系统。最终用途主要是医疗设施、研究机构和专科诊所，以进行这些治疗和管理患者护理。

主要市场统计
基准年[2023] 15亿美元
预测年份 [2024] 15.9亿美元
预测年份 [2030] 22.1亿美元
复合年增长率（%） 5.61%

市场成长在很大程度上受到生物技术进步和对罕见遗传疾病认识不断提高的影响，导致对更准确诊断和有效治疗的需求增加。此外，政府透过孤儿药指定和津贴来支持研究工作和药物开发，为成长铺平道路。个人化医疗的扩展以及CRISPR等新基因编辑技术的整合有望成为突破性的治疗方法。然而，高昂的治疗成本、有限的患者数量和严格的监管流程等挑战构成了重大限制，影响了市场扩张。开发安全有效的治疗方法的复杂性也阻碍了新兴企业进入市场。

该领域的创新应侧重于增强酶替代疗法的传递系统、推进基因治疗技术以及改进诊断工具以实现早期和准确的检测。扩大合作研究倡议并探索与生物技术公司的策略伙伴关係可以提供宝贵的见解和资源并推动市场成长。儘管庞贝氏症市场的性质相对较小，但随着技术能力的发展，预计将取得重大进展，使尖端研究能够利用尖端研究实现治疗创新，同时克服高成本和监管障碍。

市场动态：揭示快速发展的庞贝氏症市场的关键市场洞察

供需的动态交互作用正在改变庞贝氏症市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 庞贝氏症的蔓延
    • 长期治疗的普及和诊疗的进步
    • 基因疗法和酵素替代疗法的发展加快
  • 市场限制因素
    • 庞贝氏症治疗费用高昂
  • 市场机会
    • 加大研发投入
    • 政府致力于开发和製造创新产品
  • 市场问题
    • 缺乏治疗意识

波特五力：驾驭庞贝氏症市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解庞贝氏症市场的外部影响

外部宏观环境因素在塑造庞贝氏症市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解庞贝氏症市场的竞争格局

对庞贝氏症市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：庞贝氏症市场供应商绩效评估

FPNV定位矩阵是评估庞贝氏症市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製庞贝氏症市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，庞贝氏症市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：详细检视当前市场环境，主要企业的广泛资料，评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 庞贝氏病患病率增加
      • 长期治疗的普及和诊疗的进步
      • 基因疗法和酵素替代疗法的进展
    • 抑制因素
      • 庞贝氏症的治疗费用昂贵
    • 机会
      • 加大研发投入
      • 政府致力于开发和製造创新产品
    • 任务
      • 缺乏治疗意识
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章庞贝氏症市场：依治疗类型

  • 介绍
  • 酵素
  • 基板

第七章庞贝氏症市场：依分子类型

  • 介绍
  • 生技药品
  • 小分子

第八章庞贝氏症市场：按剂型

  • 介绍
  • 液体
  • 固体的

第九章庞贝氏症市场：依给药途径

  • 介绍
  • 口服
  • 由监护人

第十章美洲庞贝氏症市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太庞贝氏症市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲庞贝病市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Astellas Pharma Europe Ltd
  • B Braun Melsungen AG
  • Becton, Dickinson & Company
  • CENTOGENE NV
  • Flowserve Corporation
  • Genethon
  • GlaxoSmithKline PLC
  • Koninklijke Philips NV
  • Merck KGaA
  • Novartis AG
  • Oxyrane UK Ltd.
  • Pfizer Inc.
  • Pharming Group NV
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-035AB9C0DAD1

The Pompe Disease Market was valued at USD 1.50 billion in 2023, expected to reach USD 1.59 billion in 2024, and is projected to grow at a CAGR of 5.61%, to USD 2.21 billion by 2030.

Pompe Disease, a rare inherited disorder resulting from the buildup of glycogen in the body's cells, presents a unique market landscape characterized by specialized therapeutic needs and challenges. The scope of the market centers on enzyme replacement therapies and potential gene therapies to address varying forms of the disease, ranging from infantile-onset to late-onset Pompe Disease. The necessity for treatment is underscored by the disease's debilitating nature, which impacts cardiac and skeletal muscles, emphasizing the vital role of ongoing medical intervention. Key application areas include genetic research, enzyme development, and patient management systems. End-use primarily involves healthcare facilities, research institutes, and specialty clinics equipped to administer these treatments and manage patient care.

KEY MARKET STATISTICS
Base Year [2023] USD 1.50 billion
Estimated Year [2024] USD 1.59 billion
Forecast Year [2030] USD 2.21 billion
CAGR (%) 5.61%

Market growth is significantly influenced by advances in biotechnology and increasing awareness of rare genetic disorders, leading to more accurate diagnoses and increased demand for effective treatments. Furthermore, governmental support through orphan drug designations and grants propels research endeavors and drug development, creating avenues for growth. Potential opportunities abound in the expansion of personalized medicine and the integration of novel gene-editing technologies like CRISPR, which hold promise for groundbreaking interventions. However, challenges such as high treatment costs, limited patient population, and stringent regulatory processes pose considerable limitations and impact market expansion. The complexity of developing safe and effective therapies also deters market entry for new firms.

Innovation in this field should focus on enhancing delivery systems for enzyme replacement therapies, advancing genetic therapy techniques, and improving diagnostic tools for early and accurate detection. Expanding collaborative research initiatives and exploring strategic partnerships with biotech firms can provide valuable insights and resources, fostering market growth. The nature of the Pompe Disease market is relatively niche yet poised for substantial advancement as technological capabilities evolve, presenting significant potential for firms that can navigate the high barriers of cost and regulation while leveraging cutting-edge research for therapeutic innovation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pompe Disease Market

The Pompe Disease Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of pompe disease
    • Uptake of long term therapies and advancement in the diagnosis and treatment
    • Increasing developments in the gene therapy and enzyme replacement therapies
  • Market Restraints
    • High treatment costs of pompe diseases
  • Market Opportunities
    • Increasing investment in the research and development
    • Government initiatives for the development and manufacture of innovative products
  • Market Challenges
    • Lack of awareness about the treatment

Porter's Five Forces: A Strategic Tool for Navigating the Pompe Disease Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pompe Disease Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pompe Disease Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pompe Disease Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pompe Disease Market

A detailed market share analysis in the Pompe Disease Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pompe Disease Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pompe Disease Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Pompe Disease Market

A strategic analysis of the Pompe Disease Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Pompe Disease Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Europe Ltd, B Braun Melsungen AG, Becton, Dickinson & Company, CENTOGENE N.V., Flowserve Corporation, Genethon, GlaxoSmithKline PLC, Koninklijke Philips NV, Merck KGaA, Novartis AG, Oxyrane UK Ltd., Pfizer Inc., Pharming Group NV, Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Pompe Disease Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapy Type, market is studied across Enzyme and Substrate.
  • Based on Molecule Type, market is studied across Biologics and Small Molecules.
  • Based on Dosage Form, market is studied across Liquid and Solid.
  • Based on Route of Administration, market is studied across Oral and Parental.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of pompe disease
      • 5.1.1.2. Uptake of long term therapies and advancement in the diagnosis and treatment
      • 5.1.1.3. Increasing developments in the gene therapy and enzyme replacement therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High treatment costs of pompe diseases
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investment in the research and development
      • 5.1.3.2. Government initiatives for the development and manufacture of innovative products
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness about the treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pompe Disease Market, by Therapy Type

  • 6.1. Introduction
  • 6.2. Enzyme
  • 6.3. Substrate

7. Pompe Disease Market, by Molecule Type

  • 7.1. Introduction
  • 7.2. Biologics
  • 7.3. Small Molecules

8. Pompe Disease Market, by Dosage Form

  • 8.1. Introduction
  • 8.2. Liquid
  • 8.3. Solid

9. Pompe Disease Market, by Route of Administration

  • 9.1. Introduction
  • 9.2. Oral
  • 9.3. Parental

10. Americas Pompe Disease Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Pompe Disease Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Pompe Disease Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Astellas Pharma Europe Ltd
  • 2. B Braun Melsungen AG
  • 3. Becton, Dickinson & Company
  • 4. CENTOGENE N.V.
  • 5. Flowserve Corporation
  • 6. Genethon
  • 7. GlaxoSmithKline PLC
  • 8. Koninklijke Philips NV
  • 9. Merck KGaA
  • 10. Novartis AG
  • 11. Oxyrane UK Ltd.
  • 12. Pfizer Inc.
  • 13. Pharming Group NV
  • 14. Sanofi S.A.
  • 15. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. POMPE DISEASE MARKET RESEARCH PROCESS
  • FIGURE 2. POMPE DISEASE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL POMPE DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL POMPE DISEASE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL POMPE DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS POMPE DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS POMPE DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES POMPE DISEASE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES POMPE DISEASE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA POMPE DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA POMPE DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. POMPE DISEASE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. POMPE DISEASE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. POMPE DISEASE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL POMPE DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL POMPE DISEASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL POMPE DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. POMPE DISEASE MARKET DYNAMICS
  • TABLE 7. GLOBAL POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL POMPE DISEASE MARKET SIZE, BY ENZYME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL POMPE DISEASE MARKET SIZE, BY SUBSTRATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL POMPE DISEASE MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL POMPE DISEASE MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL POMPE DISEASE MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL POMPE DISEASE MARKET SIZE, BY SOLID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL POMPE DISEASE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL POMPE DISEASE MARKET SIZE, BY PARENTAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS POMPE DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES POMPE DISEASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. INDIA POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDONESIA POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. JAPAN POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. MALAYSIA POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. PHILIPPINES POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. SINGAPORE POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. SOUTH KOREA POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. TAIWAN POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. THAILAND POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. VIETNAM POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA POMPE DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 103. DENMARK POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. EGYPT POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. FINLAND POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. FRANCE POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. GERMANY POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. ISRAEL POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. ITALY POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. NETHERLANDS POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. NIGERIA POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. NORWAY POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. POLAND POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. QATAR POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. RUSSIA POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. SAUDI ARABIA POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH AFRICA POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. SPAIN POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SWEDEN POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. SWITZERLAND POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. TURKEY POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. UNITED ARAB EMIRATES POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. POMPE DISEASE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 188. POMPE DISEASE MARKET, FPNV POSITIONING MATRIX, 2023